LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.

    Thuluva, Subhash / Gunneri, SubbaReddy / Turaga, Kishore / Mogulla, Rammohan Reddy / Yerroju, Vijay / Peta, Kalyankumar / Suneetha, Pothakamuri Venkata / Matur, Ramesh V

    Contemporary clinical trials communications

    2023  Volume 36, Page(s) 101232

    Abstract: Measles is a major cause of childhood mortality and one-third of the world's Measles deaths occur in India. Rubella causes lifelong birth defects (Congenital Rubella Syndrome). Although neither condition has a cure, the MR vaccination can successfully ... ...

    Abstract Measles is a major cause of childhood mortality and one-third of the world's Measles deaths occur in India. Rubella causes lifelong birth defects (Congenital Rubella Syndrome). Although neither condition has a cure, the MR vaccination can successfully prevent both diseases. The safety of Biological E's live attenuated MR vaccine (BE-MR) was established in 4-5-year-old healthy children. This phase-2/3 study was conducted to assess the safety and immunogenicity of BE-MR in 9-12 month old healthy infants. Overall, 600 subjects were enrolled and equally randomized to receive either BE-MR (n = 300) or the comparator vaccine, SII MR-Vac™ (n = 300). Safety profile of BE-MR vaccine was comparable to SII MR-Vac™ with no severe or serious adverse events (AEs) reported across the study groups. The primary objective of demonstrating non inferiority by BE-MR vaccine compared to SIIL's-MR Vac™ was met. The proportion of subjects with ≥ 2-fold and ≥ 4-fold increase in antibody titre against Measles and Rubella in both the study groups was comparable. Overall, BE-MR vaccine elicited robust and protective immune response as demonstrated by high proportion of sero-protected subjects and a large increase in anti-Measles and anti-Rubella antibodies at day 42 and can be administered safely to infants below one-year of age. This study was prospectively registered with the clinical trial registry of India- CTRI/2016/07/007109.
    Language English
    Publishing date 2023-11-22
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2451-8654
    ISSN (online) 2451-8654
    DOI 10.1016/j.conctc.2023.101232
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.

    Matur, Ramesh V / Thuluva, Subhash / Gunneri, Subbareddy / Yerroju, Vijay / Reddy Mogulla, Rammohan / Thammireddy, Kamal / Paliwal, Piyush / Mahantshetty, Niranjana S / Ravi, Mandyam Dhati / Prashanth, S / Verma, Savita / Narayan, Jai Prakash

    Vaccine

    2024  Volume 42, Issue 13, Page(s) 3157–3165

    Abstract: Background: Introduction of pneumococcal conjugate vaccines (PCVs) reduced the number of cases of pneumococcal disease (PD). However, there is an increase in clinical and economic burden of PD from serotypes that are not part of the existing ... ...

    Abstract Background: Introduction of pneumococcal conjugate vaccines (PCVs) reduced the number of cases of pneumococcal disease (PD). However, there is an increase in clinical and economic burden of PD from serotypes that are not part of the existing pneumococcal vaccines, particularly impacting pediatric and elder population. In addition, the regions where the PCV is not available, the disease burden remains high. In this study, immunogenicity and safety of the BE's 14-valent PCV (PNEUBEVAX 14™; BE-PCV-14) containing two additional epidemiologically important serotypes (22F and 33F) was evaluated in infants in comparison to licensed vaccine, Prevenar-13 (PCV-13).
    Methods: This is a pivotal phase-3 single blind randomized active-controlled study conducted at 12 sites across India in 6-8 weeks old healthy infants at 6-10-14 weeks dosing schedule to assess immunogenic non-inferiority and safety of a candidate BE-PCV-14. In total, 1290 infants were equally randomized to receive either BE-PCV-14 or PCV-13. Solicited local reactions and systemic events, adverse events (AEs), serious AEs (SAEs), and medically attended AEs (MAAEs) were recorded. Immunogenicity was assessed by measuring anti-PnCPS (anti-pneumococcal capsular polysaccharide) IgG concentration and functional antibody titers through opsonophagocytic activity (OPA), one month after completing three dose schedule. Cross protection to serotype 6A offered by serotype 6B was also assessed in this study.
    Findings: The safety profile of BE-PCV-14 was comparable to PCV-13 vaccine. Majority of reported AEs were mild in nature. No severe or serious AEs were reported in both the treatment groups. For the twelve common serotypes and for the additional serotypes (22F and 33F) in BE-PCV-14, NI criteria was demonstrated as defined by WHO TRS-977. Primary immunogenicity endpoint was met in terms of IgG immune responses for all 14 serotypesof BE-PCV-14. Moreover, a significant proportion of subjects (69%) seroconverted against serotype 6A, even though this antigen was not present in BE-PCV-14. This indicates that serotype 6B of BE-PCV-14 cross protects serotype 6A. BE-PCV-14 also elicited comparable serotype specific functional OPA immune responses to all the serotypes common to PCV-13.
    Interpretations: BE-PCV-14 was found to be safe and induced robust and functional serotype specific immune responses to all 14 serotypes. It also elicited cross protective immune response against serotype 6B.These findings suggest that BE-PCV-14 can be safely administered to infants and achieve protection against pneumococcal disease caused by serotypes covered in the vaccine. The study was prospectively registered with clinical trial registry of India - CTRI/2020/02/023129.
    MeSH term(s) Humans ; Pneumococcal Vaccines/immunology ; Pneumococcal Vaccines/adverse effects ; Pneumococcal Vaccines/administration & dosage ; Infant ; India ; Antibodies, Bacterial/blood ; Male ; Vaccines, Conjugate/immunology ; Vaccines, Conjugate/adverse effects ; Vaccines, Conjugate/administration & dosage ; Female ; Pneumococcal Infections/prevention & control ; Pneumococcal Infections/immunology ; Single-Blind Method ; Streptococcus pneumoniae/immunology ; Immunogenicity, Vaccine ; Serogroup ; Immunoglobulin G/blood
    Chemical Substances Pneumococcal Vaccines ; Antibodies, Bacterial ; Vaccines, Conjugate ; Immunoglobulin G ; 13-valent pneumococcal vaccine
    Language English
    Publishing date 2024-04-17
    Publishing country Netherlands
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't ; Clinical Trial, Phase III ; Multicenter Study
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2024.03.056
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.

    Thuluva, Subhash / Paradkar, Vikram / Gunneri, SubbaReddy / Yerroju, Vijay / Mogulla, Rammohan / Suneetha, Pothakamuri Venkata / Turaga, Kishore / Kyasani, Mahesh / Manoharan, Senthil Kumar / Adabala, Srikanth / Sri Javvadi, Aditya / Medigeshi, Guruprasad / Singh, Janmejay / Shaman, Heena / Binayke, Akshay / Zaheer, Aymaan / Awasthi, Amit / Singh, Chandramani / Rao A, Venkateshwar /
    Basu, Indranil / Kumar, Khobragade Akash Ashok / Pandey, Anil Kumar

    Human vaccines & immunotherapeutics

    2023  Volume 19, Issue 1, Page(s) 2203632

    Abstract: Optimum formulation of Biological-E's protein subunit CORBEVAX™ vaccine was selected in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. This is a phase-3 prospective, single-blinded, randomized, active controlled ... ...

    Abstract Optimum formulation of Biological-E's protein subunit CORBEVAX™ vaccine was selected in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. This is a phase-3 prospective, single-blinded, randomized, active controlled study conducted at 18 sites across India in 18-80 year-old subjects. This study has two groups; (i) immunogenicity-group, participants randomized either to CORBEVAX™ (
    MeSH term(s) Adult ; Humans ; Adolescent ; Young Adult ; Middle Aged ; Aged ; Aged, 80 and over ; ChAdOx1 nCoV-19 ; COVID-19 Vaccines/adverse effects ; Leukocytes, Mononuclear ; Prospective Studies ; Single-Blind Method ; COVID-19/prevention & control ; SARS-CoV-2 ; Vaccines ; Immunogenicity, Vaccine ; Antibodies, Viral ; Antibodies, Neutralizing ; Double-Blind Method
    Chemical Substances ChAdOx1 nCoV-19 (B5S3K2V0G8) ; COVID-19 Vaccines ; Vaccines ; Antibodies, Viral ; Antibodies, Neutralizing
    Language English
    Publishing date 2023-04-27
    Publishing country United States
    Document type Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase III ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2664176-8
    ISSN 2164-554X ; 2164-5515
    ISSN (online) 2164-554X
    ISSN 2164-5515
    DOI 10.1080/21645515.2023.2203632
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Immunogenicity and safety of Biological Es CORBEVAX vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD or COVAXIN: A Prospective double-blind randomised phase III clinical study

    Thuluva, Subhash / Paradkar, Vikram / Gunneri, Subbareddy / Yerroju, Vijay / Mogulla, Rammohan Reddy / Venkata Suneetha, Pothakamuri / Turaga, Kishore / Binayke, Akshay / Zaheer, Aymaan / Awasti, Amit / Virkar, Rashmi / Narang, Manish / Nanjappa, Pradeep / Mahantshetti, Niranjan / Garg, BishanSwarup / Mandal, RavindraNath

    medRxiv

    Abstract: Background:Vaccines developed against Covid-19 infection were effective in controlling symptomatic infections and hospitalizations. However, waning immunity was reported within 6 months of primary vaccination series. Due to waning of SARS-CoV-2 specific ... ...

    Abstract Background:Vaccines developed against Covid-19 infection were effective in controlling symptomatic infections and hospitalizations. However, waning immunity was reported within 6 months of primary vaccination series. Due to waning of SARS-CoV-2 specific primary immunity, protection towards emerging variants of concern (VoC) was low. To rejuvenate the immunogenicity of vaccines, a third or booster dose was highly recommended by many state governments. In this regard, several clinical studies were conducted to evaluate the homologous or heterologous booster dose effectiveness against VoCs and showed that heterologous immune boosting more effective in controlling breakthrough infections. In this study, we studied the safety and immunogenicity of Biological-Es CORBEVAX vaccine in adult population as a heterologous booster dose. Methods: This is a prospective phase-3, randomised, double-blind, placebo-controlled, study evaluating safety, reactogenicity, tolerability and immunogenicity of CORBEVAX vaccine as a heterologous booster dose administered to adult volunteers previously vaccinated with two doses of either COVISHIELD or COVAXIN at least 6 months ago. Subjects were RT-PCR negative to SARS-CoV-2 prior to enrolment. A total of 416 subjects between 18 to 80 years of age, were enrolled in to one of the two treatment (COVISHIELD or COVAXIN primed subjects) groups (n=208/group) for safety and immunogenicity assessment. Within each group (n=208), subjects were randomized to receive CORBEVAX vaccine or placebo in a 3:1 ratio. Findings: The safety profile of CORBEVAX vaccine administered as booster dose is comparable to the placebo-control group. All the reported adverse events (AEs) were mild to moderate in their intensity. There was no grade 3 or serious or AEs of special interest (AESI) reported during the study period and all the reported AEs resolved without any sequelae. CORBEVAX booster dose administration resulted in significant increase in humoral immune response (nAb titers and Anti-RBD IgG concentration) that was much superior to the placebo in both COVISHIELD and COVAXIN recipient arms. Significant increase in nAb titers against Omicron VOC as well as cellular immune response was also observed post CORBEVAX booster dose administration. Interpretations: Enhancement of immune response coupled with excellent safety profile of the CORBEVAX booster dose demonstrates significant benefit of giving CORBEVAX heterologous booster dose to subjects that have received COVISHIELD or COVAXIN primary vaccination, as early as 6 months post second dose of primary vaccination.
    Keywords covid19
    Language English
    Publishing date 2023-01-03
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.12.29.22284049
    Database COVID19

    Kategorien

  5. Article ; Online: Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies

    Thuluva, Subhash / Paradkar, Vikram / Turaga, Kishore / Gunneri, Subbareddy / Yerroju, Vijay / Mogulla, Rammohanreddy / Kyasani, Mahesh / Manoharan, Senthilkumar / Medigeshi, Guruprasad R / Singh, JANMEJAY / Shaman, Heena / Singh, Chandramani / Rao A, Venkateshwar

    medRxiv

    Abstract: Background- We present the data from an open-label study involved in the selection of optimum formulation of RBD-based protein sub-unit COVID-19 vaccine. Methods- The randomized Phase-1/2 trial followed by a Phase-2 trial was carried out to assess safety ...

    Abstract Background- We present the data from an open-label study involved in the selection of optimum formulation of RBD-based protein sub-unit COVID-19 vaccine. Methods- The randomized Phase-1/2 trial followed by a Phase-2 trial was carried out to assess safety and immunogenicity of different formulation of COVID-19 vaccine (Corbevax) and select an optimum formulation for a phase 3 study. Healthy adults without a history of Covid-19 vaccination or SARS-CoV-2 infection, were enrolled. Findings- Low incidence of AEs were reported post vaccination of different Corbevax formulations and majority were mild in nature and no Grade-3 or serious AEs were observed. All formulations in Phase-1/2 study showed similar profile of humoral and cellular immune-response with higher response associated with increasing CpG1018 adjuvant content at same RBD protein content. Hence, high concentration of CpG1018 was tested in phase-2 study, which showed significant improvement in immune-responses in terms of anti-RBD-IgG concentrations, anti-RBD-IgG1 titers, nAb-titers and cellular immune-responses while maintaining the safety profile. Interestingly, binding and neutralizing antibody titers were persisted consistently till 6 months post second vaccine dose. Interpretations- Corbevax was well tolerated with no observed safety concerns. Neutralizing antibody titers were suggestive of high vaccine effectiveness compared with human convalescent plasma or protective thresholds observed during vaccine efficacy trials of other COVID-19 vaccines. The study was prospectively registered with clinical trial registry of India- CTRI/2021/06/034014 and CTRI/2020/11/029032. Funding: Bill and Melinda Gates Foundation, BIRAC- division of Department of Biotechnology, Govt of India, and the Coalition for Epidemic Preparedness Innovations funded the study.
    Keywords covid19
    Language English
    Publishing date 2022-03-09
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.03.08.22271822
    Database COVID19

    Kategorien

  6. Article ; Online: Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.

    Thuluva, Subhash / Paradkar, Vikram / Gunneri, SubbaReddy / Yerroju, Vijay / Mogulla, Rammohan Reddy / Suneetha, Pothakamuri Venkata / Turaga, Kishore / Kyasani, Mahesh / Manoharan, Senthil Kumar / Adabala, Srikanth / Sri Javvadi, Aditya / Medigeshi, Guruprasad / Singh, Janmejay / Shaman, Heena / Binayke, Akshay / Zaheer, Aymaan / Awasthi, Amit / Narang, Manish / Nanjappa, Pradeep /
    Mahantshetti, Niranjana / Swarup Garg, Bishan / Pandey, Anil Kumar

    Vaccine

    2022  Volume 40, Issue 49, Page(s) 7130–7140

    Abstract: Background: After establishing safety and immunogenicity of Biological-E's CORBEVAX™ vaccine in adult population (18-80 years) in Phase 1-3 studies, vaccine is further tested in children and adolescents in this study.: Methods: This is a phase-2/3 ... ...

    Abstract Background: After establishing safety and immunogenicity of Biological-E's CORBEVAX™ vaccine in adult population (18-80 years) in Phase 1-3 studies, vaccine is further tested in children and adolescents in this study.
    Methods: This is a phase-2/3 prospective, randomised, double-blind, placebo-controlled study evaluating safety, reactogenicity, tolerability and immunogenicity of CORBEVAX™ vaccine in children and adolescents of either gender between <18 to ≥12 years of age in Phase-2 and <18 to ≥5 years of age in Phase-Phase-2/Phase-3 with placebo as a control. This study has two age sub-groups; subgroup-1 with subjects <18 to ≥12 years of age and subgroup-2 with subjects <12 to ≥5 years of age. In both sub groups, eligible subjects (SARS-CoV-2 RT-PCR negative and seronegative at baseline) were randomized to receive either CORBEVAX™ vaccine or Placebo in 3:1 ratio.
    Findings: The safety profile of CORBEVAX™ vaccine in both pediatric cohorts was comparable to the placebo-control group. Majority of reported adverse events (AEs) were mild in nature. No severe or serious-AEs, medically attended AEs (MAAEs) or AEs of special interest (AESI) were reported during the study period and all reported AEs resolved without any sequelae. In both pediatric age groups, CORBEVAX™ vaccinated subjects showed significant improvement in humoral immune-responses in terms of anti-RBD-IgG concentrations, anti-RBD-IgG1 titers, neutralizing-antibody (nAb)-titers against Ancestral-Wuhan and Delta-strains. Significantly high interferon-gamma immune- response (cellular) was elicited by CORBEVAX™ vaccinated subjects with minimal effect on IL-4 cytokine secretion.
    Interpretations: The safety profile of CORBEVAX™ vaccine in <18 to ≥5 years' children and adolescents was found to be safe and tolerable. Significant increase in anti-RBD-IgG and nAb-titers and IFN-gamma immune-responses were observed post-vaccination in both pediatric age sub-groups. The nAb titers observed in both the pediatric age cohorts were non-inferior to the adult cohort (BECT069 study) in terms of ratio of the GMT's of both the cohorts. This study shows that CORBEVAX™ vaccine is highly immunogenic and can be safely administered to pediatric population as young as 5 years old. The study was prospectively registered with clinical trial registry of India- CTRI/2021/10/037066.
    MeSH term(s) Adult ; Humans ; Child ; Adolescent ; Child, Preschool ; SARS-CoV-2 ; Prospective Studies ; COVID-19/prevention & control ; Vaccines ; Double-Blind Method ; Immunoglobulin G ; Immunogenicity, Vaccine ; Antibodies, Viral ; Antibodies, Neutralizing
    Chemical Substances Vaccines ; Immunoglobulin G ; Antibodies, Viral ; Antibodies, Neutralizing
    Language English
    Publishing date 2022-10-31
    Publishing country Netherlands
    Document type Randomized Controlled Trial ; Clinical Trial, Phase II ; Clinical Trial, Phase III ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2022.10.045
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Immunogenic superiority and safety of Biological E CORBEVAX vaccine compared to COVISHIELD (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial

    Thuluva, Subhash / Paradkar, Vikram / Turaga, Kishore / Gunneri, Subbareddy / Yerroju, Vijay / Mogulla, Rammohan Reddy / Pothakamuri, Venkata Suneetha / Kyasani, Mahesh / Manoharan, Senthilkumar / Adabala, Srikanth / Javvadi, Aditya Sri / Medigeshi, Guruprasad R / Singh, Janmejay / Shaman, Heena / Binayke, Akshay / Zaheer, Aymaan / Awasrhi, Amit / Singh, Chandramani / A, Venkateshwar Rao /
    Basu, Indranil / Khobragade, Akash Ashok Kumar / Pandey, Anil Kumar

    medRxiv

    Abstract: Background: Optimum formulation of Biological Es CORBEVAX vaccine that contains protein sub unit of Receptor Binding Domain (RBD) from the spike protein of SARS-COV-2 formulated with aluminum hydroxide (Al3+) and CpG1018 as adjuvants was selected in ... ...

    Abstract Background: Optimum formulation of Biological Es CORBEVAX vaccine that contains protein sub unit of Receptor Binding Domain (RBD) from the spike protein of SARS-COV-2 formulated with aluminum hydroxide (Al3+) and CpG1018 as adjuvants was selected in phase-1 and 2 studies and proven to be safe, well tolerated and immunogenic in healthy adult population. In the current study, additional data was generated to determine immunogenic superiority of CORBEVAX vaccine over COVISHIELD vaccine and safety in larger and older population. Methods: This is a phase III prospective, single blinded, randomized, active controlled study (CTRI/2021/08/036074) conducted at 18 sites across India in healthy adults aged between 18-80 years. This study has two arms; immunogenicity arm and safety arm. Participants in immunogenicity arm were randomized equally to either CORBEVAX or COVISHIELD vaccination groups to determine the immunogenic superiority. Healthy adults without a history of Covid-19 vaccination or SARS-CoV-2 infection, were enrolled. Findings: The safety profile of CORBEVAX vaccine was comparable to the comparator vaccine COVISHIELD in terms of overall AE rates, related AE rates and medically attended AEs. Majority of reported AEs were mild in nature, and overall CORBEVAX appeared to cause fewer local and systemic adverse reactions/events. Overall, two grade-3 serious AEs (Dengue fever and femur fracture) were reported and they are unrelated to study vaccine. Neutralizing Antibody titers, against both Ancestral and Delta strain, induced post two-dose vaccination regimen were higher in the CORBEVAX arm as compared to COVISHIELD and the analysis of GMT ratios demonstrated immunogenic superiority of CORBEVAX in comparison with COVISHIELD. Both CORBEVAX and COVISHIELD vaccines showed comparable seroconversion post vaccination when assessed against anti-RBD IgG response. The subjects in CORBEVAX cohort also exhibited higher Interferon-gamma secreting PBMCs post stimulation with SARS-COV-2 RBD peptides than the subjects in COVISHIELD cohort. Interpretations: Neutralizing antibody titers induced by CORBEVAX vaccine against Delta and Ancestral strains were protective, indicative of vaccine effectiveness of >90% for prevention of symptomatic infections based on the Correlates of Protection assessment performed during Moderna and Astra-Zeneca vaccine Phase III studies. Safety findings revealed that CORBEVAX vaccine has excellent safety profile when tested in larger and older population.
    Keywords covid19
    Language English
    Publishing date 2022-03-22
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.03.20.22271891
    Database COVID19

    Kategorien

  8. Article ; Online: Safety, tolerability and immunogenicity of Biological Es CORBEVAX vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study.

    Thuluva, Subhash / Paradkar, Vikram / Gunneri, Subbareddy / Yerroju, Vijay / Mogulla, Rammohan / Pothakamuri, Suneetha Venkata / Turaga, Kishore / Kyasani, Mahesh / Manoharan, Senthilkumar / Adabala, Srikanth / Javvadi, Aditya Sri / Medigeshi, Guruprasad R / Singh, Janmejay / Shaman, Heena / Binayke, Akshay / Aymaan, Zaheer / Awasthi, Amit / Narang, Manish / N, Pradeep /
    Mahantshetti, Niranjan / Garg, Bishan Swarup / Ravi, Mandal

    medRxiv

    Abstract: Background: After establishing safety and immunogenicity of Biological Es CORBEVAX vaccine in adult population (18-80 years) in Phase 1-3 studies, vaccine is further tested in children and adolescents in this study. Methods: This is a phase-2/3 ... ...

    Abstract Background: After establishing safety and immunogenicity of Biological Es CORBEVAX vaccine in adult population (18-80 years) in Phase 1-3 studies, vaccine is further tested in children and adolescents in this study. Methods: This is a phase-2/3 prospective, randomised, double-blind, placebo controlled, study evaluating safety, reactogenicity, tolerability and immunogenicity of CORBEVAX vaccine in children and adolescents of either gender between 17 to 12 years of age in Phase-II and 17-5 years of age in Phase-III with placebo as a control. This study has two age sub groups; age subgroup-1 with subjects 17 to 12 years of age and age subgroup-2 with subjects 11 to 5 years of age. In both age sub groups eligible subjects (SARS-CoV-2 RT-PCR negative and seronegative at baseline) were randomized to receive either CORBEVAX vaccine or Placebo in 3: 1 ratio. Findings: The safety profile of CORBEVAX vaccine in both pediatric cohorts was comparable to the placebo control group. Majority of reported adverse events (AEs) were mild in nature. No severe or serious AEs, medically attended AEs (MAAEs) or AEs of special interest (AESI) were reported during the study period and all the reported AEs resolved without any sequelae. In both pediatric age groups, CORBEVAX vaccinated subjects showed significant improvement in humoral immune-responses in terms of anti-RBD-IgG concentrations, anti-RBD-IgG1 titers, neutralizing antibody (nAb)-titers against Ancestral Wuhan and Delta strains. Significantly high interferon gamma immune response (cellular) was elicited by CORBEVAX vaccinated subjects with minimal effect on IL-4 cytokine secretion. Interpretations: The safety profile of CORBEVAX vaccine in 17 to 5 years children and adolescents was found to be safe and tolerable. The adverse event profile was also found to be acceptable. Significant increase in anti-RBD IgG and nAb titers and IFN-gamma immune responses were observed post vaccination in both pediatric age sub groups. Both humoral and cellular immune responses were found to be non-inferior to the immune responses induced by CORBEVAX vaccine in adult population. This study shows that CORBEVAX vaccine is highly immunogenic and can be safely administered to pediatric population as young as 5 years old.
    Keywords covid19
    Language English
    Publishing date 2022-04-26
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.04.20.22274076
    Database COVID19

    Kategorien

To top